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RT, is an effective way of achieving intrathoracic local 
control.  Patients with locally advanced or metastatic disease 
frequently experience morbidity or mortality due to the 
consequences of local disease progression.  Patients with 
large, central disease or compression of major bronchi or 
vessels were found to have worse overall survival (OS) in a 
pooled analysis of patients enrolled in clinical trials involving 
first-line, platinum-based chemotherapy, suggesting that 
improvement in local control with the addition of  thoracic 
RT to systemic therapy could improve OS. (2)   
Preclinical data suggests that the combination of molecularly 
targeted agents and RT increases radiation responsiveness.  
To date, the combination has not improved outcomes in 
clinical trials in patients with locally advanced NSCLC (3). 
Studies addressing the choice of agent to be used in 
combination and in particular the optimal sequencing of 
modalities are required. 
  
(1) Fairchild A et al: J Clin Oncol 2008: 26(24): 4001-4011. 
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Resection of liver metastases from colorectal carcinoma 
(CRC) is associated with 5 year survival rates of 
approximately 50% with the possibility for cure.  Although 
long term survivors have also been reported following 
resection of liver metastases from sarcoma, renal cell 
carcinoma, breast cancer and melanoma (5 year survival up 
to 36%), resection is not routinely accepted as standard of 
care.  As the risks of surgery increase, and the benefits of 
surgery decline, alternative local ablative therapies such as 
radiofrequency ablation (RFA) and stereotactic body 
radiation therapy (SBRT) are more attractive treatment 
options.    
Hepatic arterial directed chemotherapy (or chemo-ablation) 
has been used to treat liver metastases from CRC with better 
than expected results compared with systemic therapy in 
single institutional series, but there are no comparative 
studies with modern chemotherapy for CRC or other liver 
metastases.  This therapy is not considered ablative, with the 
potential to cure.  
Radiofrequency ablation (RFA) is an effective ablative 
technique for liver metastases treatment.  Local control is 
highest (> 80%) in selected metastases < 3 cm in maximal 
diameter.  Recurrences are common in metastases > 5 cm, or 
in metastases adjacent to large vessels that may act as a 
heat sink.  Primary toxicities include infection and bleeding.  
RFA of lesions near the common bile duct or diaphragm are 
associated with increased risks of serious toxicity.  
Stereotactic body radiation therapy (SBRT) is an attractive 
option for patients with liver metastases.  Short course, out-
patient SBRT delivered in 1 to 10 fractions is convenient for 
patients, with little ‘downtime’, and short systemic therapy 
break.  Liver SBRT requires a planning CT simulation scan 
with IV contrast and/or contrast-enhanced MRI for target 
delineation. Breathing related liver motion should be 
assessed by respiratory correlated (or 4D) CT, cine-MR 
imaging or 2D kV fluoroscopy to determine appropriate 
planning target volume (PTV) margins.  Highly conformal dose 
distributions are desirable using multiple beams or arcs, in 
coplanar or non-coplanar geometries.  Immobilization of the 
liver using controlled breath holds, abdominal compression, 
gating of the RT beam during specified phases of the 
respiratory cycle, medications, or tumor tracking may help 
reduce the adverse effects of breathing motion.  Image 
guided RT (IGRT) based on volumetric imaging such as kV 
cone beam CT, is required at every fraction in order to 
reduce PTV margins.  MR IGRT is an area of active research 
that may benefit liver SBRT.   
A Toronto SBRT study (24 – 48 Gy in 6 fractions) in 107 
patients with 172 inoperable liver metastases from colon, 
breast cancer or other sites (median volume 75 cc) had a 
median survival of 18.1 months.  Survival was worse in 
patients with extrahepatic disease (present in 43%).  
Improved local control was seen with breast cancer and 
higher doses.  Some patients appear cured > 5 years post 
SBRT.   Other SBRT series (30-60 Gy in 1-6 fractions) for < 5 
metastases (maximal size < 6 cm) have reported median 
survival rates from 18 to 37 months, and local control of 67% 
to 100%.   A dose response has been observed in most series, 
with increased chance of sustained local control (80 – 90% at 
2 years) when doses higher than 42 Gy in 3 fractions are 
used.  Local control is also improved in patients with 
metastases less than 3 cm in maximal size and in breast 
cancer metastases compared to colorectal cancer 
metastases.  Local control may be reduced in metastases 
adjacent to luminal gastrointestinal tissues.  SBRT has low 
acute and late toxicity (transient fatigue, nausea, gastritis or 
duodenitis), and very low risk of liver toxicity.  Chest wall 
and rib fractures have also occasionally been seen.  Studies 
have shown that quality of life is preserved 3 – 12 months 
post SBRT. The most suitable patients are those with 5 or 
fewer metastases, < 6 cm, with no extrahepatic disease.  
More research is required regarding optimal dose-per-
fraction, as well as most appropriate patient selection and 
sequencing with systemic therapy. 
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Radiotherapy induced tumor cell kill relies on induction of 
oxidative stress. The response to irradiation of malignant 
tumors vary as a consequence of resistance mechanisms 
taking place at the molecular level. The hypoxia-inducible 
factor 1 (HIF-1) pathway is involved in various of these 
processes. With respect to metabolism HIF-1 is an important 
regulator of glycolysis and the pentose phosphate pathway. 
This aberrant cellular metabolism, responsible for 
maintaining stable intracellular ATP levels without oxygen 
consumption even under normoxic conditions, increases the 
antioxidant capacity of tumors, thereby countering the 
oxidative stress caused by irradiation. 
Interestingly, analysis of glucose transporter (GLUT1) and 
monocarboxylate transporter (MCT4) expression on the 
histological level suggested a different metabolism for 
adenocarcinomas and squamous cell carcinomas of the lung. 
Results showed that adenocarcinomas rely mainly on aerobic 
glycolysis, whereas the energy metabolism of squamous cell 
carcinomas is more physiologically, i.e. mitochondrial 
